What we do
MarketVIEW: Cholera vaccines (Sept '16)
MarketVIEW: Universal influenza vaccines (Aug '16)
MarketVIEW: RSV vaccines (Mar '16)
MarketVIEW: Zika virus vaccines (Feb '16)
MarketVIEW: HBV vaccines (Jan '16)
MarketVIEW: H.pylori vaccines (Dec '15)
MarketVIEW: Biodefense vaccines (Nov '15)
MarketVIEW: Norovirus vaccines (Oct '15)
MarketVIEW: Epstein Barr virus vaccines (Apr '15)
MarketVIEW: Metapneumovirus vaccines (Jun '15)
MarketVIEW: Ebola vaccines (April '15)
MarketVIEW: PCSK9 vaccines (Feb '15)
MarketVIEW: Parkinsons vaccines (Jan '15)
MarketVIEW: Tuberculosis vaccines (Nov '14)
MarketVIEW: Veterinary vaccines (Nov '14)
MarketVIEW: MMR-V family (Oct '14)
MarketVIEW: Allergic immunotherapies (July '14)
MarketVIEW: Herpes Zoster (Oct '14)
MarketVIEW: Rotavirus vaccines (June '14)
MarketVIEW: Group B Strep vaccines (May '14)
MarketVIEW: CMV vaccines (Apr '14)
MarketVIEW: Rabies vaccines (Mar '14)
MarketVIEW: Clostridium difficile vaccines (Dec '13)
MarketVIEW: Inactivated polio virus vaccines (Nov '13)
MarketVIEW: Chagas disease vaccines (Nov '13)
MarketVIEW: Cocaine dependence vaccines (July '13)
MarketVIEW: Ross River virus vaccines (July '13)
MarketVIEW: Diabetes vaccines (June '13)
MarketVIEW: Yellow fever vaccines (June '13)
MarketVIEW: Smoking cessation vaccines (Mar '13)
MarketVIEW: Hepatitis E virus vaccines (Feb '13)
MarketVIEW: Hepatitis C virus vaccines (Feb '13)
MarketVIEW: Alzheimer's disease vaccines (Jan '13)
MarketVIEW: West Nile vaccines (Dec '12)
MarketVIEW: Acne vaccines (Sept '12)
MarketVIEW: Candida vaccines (July '12)
MarketVIEW: HAV (Emerging) vaccines (July '12)
MarketVIEW: Enterovirus-71 (Feb '12)
MarketVIEW: meningococcus serogroup B (Jan '12)
MarketVIEW: universal pneumo (Jan '12)
MarketVIEW: Travelers' diarrhea (Oct '11)
MarketVIEW: GAS vaccines (June '11)
MarketVIEW: Melanoma vaccines (June '11)
VacZine Analytics is a strategic research publisher based in the United Kingdom since 2007.
We provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine industry.
Our key focus is helping clients build the case for developing new vaccines and immune-based therapies.
Sign up to receive news and benefits
Oct '18 (New!)
mRNA vaccines - infectious diseases
Sept '18 (New!)
Sept '18 (New!)
vaccines (endemic) -
Opioid use disorder
Pertussis booster vaccines
Staphylococcus aureus BSI/SSI vaccines
CAR-T CLL commercial forecast
CAR-T B-cell NHL commercial forecast
CAR-T B-ALL commercial forecast
CAR-T therapy overview
Pfizer's BioNTech influenza deal - the bold latecomer
An opioid use disorder (OUD) vaccine
2016 FY results - the impact of 'real use' and true product innovation.
Vaccines in the Trump era
2016 - year of the flavivirus vaccine?
2017 places higher pressure on hospitals to avoid HAIs
A Zika vaccine - the case strengthens
The global influenza vaccine market - where next?
2015 FY - Pfizer grows vaccine industry.
A Zika vaccine - late to the party we must attend.
2015 Q2 - round up of results and R&D.
Human metapneumovirus - why the poor cousin of RSV?
Tweets by @VacZineAnalytic
© 2018 VacZine Analytics. All rights reserved.
Terms and conditions
We sponsor Group B Strep Support.